

### EDG2 Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP6138a

### Specification

# EDG2 Antibody (N-term) - Product Information

Application	WB,E
Primary Accession	<u>Q92633</u>
Other Accession	<u>NP_001392</u>
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Antigen Region	21-50
Reactivity Host Clonality Isotype	Human Rabbit Polyclonal Rabbit IgG

### EDG2 Antibody (N-term) - Additional Information

Gene ID 1902

**Other Names** Lysophosphatidic acid receptor 1, LPA receptor 1, LPA-1, Lysophosphatidic acid receptor Edg-2, LPAR1, EDG2, LPA1

Target/Specificity

This EDG2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 21-50 amino acids from the N-terminal region of human EDG2.

Dilution WB~~1:1000

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

EDG2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

### EDG2 Antibody (N-term) - Protein Information

Name LPAR1

Synonyms EDG2, LPA1



Function Receptor for lysophosphatidic acid (LPA) (PubMed: 19306925, PubMed: 25025571, PubMed: 26091040, PubMed: 9070858). Plays a role in the reorganization of the actin cytoskeleton, cell migration, differentiation and proliferation, and thereby contributes to the responses to tissue damage and infectious agents. Activates downstream signaling cascades via the G(i)/G(o), G(12)/G(13), and G(q) families of heterometic G proteins. Signaling inhibits adenylyl cyclase activity and decreases cellular cAMP levels (PubMed: 26091040). Signaling triggers an increase of cytoplasmic Ca(2+) levels (PubMed: <u>19656035</u>, PubMed: <u>19733258</u>, PubMed: <u>26091040</u>). Activates RALA; this leads to the activation of phospholipase C (PLC) and the formation of inositol 1,4,5-trisphosphate (PubMed: 19306925). Signaling mediates activation of down-stream MAP kinases (By similarity). Contributes to the regulation of cell shape. Promotes Rho-dependent reorganization of the actin cytoskeleton in neuronal cells and neurite retraction (PubMed: <u>26091040</u>). Promotes the activation of Rho and the formation of actin stress fibers (PubMed: <u>26091040</u>). Promotes formation of lamellipodia at the leading edge of migrating cells via activation of RAC1 (By similarity). Through its function as LPA receptor, plays a role in chemotaxis and cell migration, including responses to injury and wounding (PubMed: 18066075, PubMed: 19656035, PubMed: 19733258). Plays a role in triggering inflammation in response to bacterial lipopolysaccharide (LPS) via its interaction with CD14. Promotes cell proliferation in response to LPA (By similarity). Inhibits the intracellular ciliogenesis pathway in response to LPA and through AKT1 activation (PubMed:<u>31204173</u>). Required for normal skeleton development. May play a role in osteoblast differentiation. Required for normal brain development. Required for normal proliferation, survival and maturation of newly formed neurons in the adult dentate gyrus. Plays a role in pain perception and in the initiation of neuropathic pain (By similarity).

### **Cellular Location**

Cell surface. Cell membrane; Multi-pass membrane protein. Endosome Note=Prior to LPA treatment found predominantly at the cell surface Internalized after LPA treatment. Colocalizes with RALA in endocytic vesicles after LPA treatment.

#### **Tissue Location**

Expressed in many adult organs, including brain, heart, colon, small intestine, placenta, prostate, ovary, pancreas, testes, spleen, skeletal muscle, and kidney. Little or no expression in liver, lung, thymus, or peripheral blood leukocytes (PubMed:9070858) Detected in lung fibroblasts from bronchoalveolar fluid from patients with idiopathic pulmonary fibrosis (PubMed:18066075). Detected in bone marrow-derived mesenchymal stem cells (PubMed:19733258)


### EDG2 Antibody (N-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

### EDG2 Antibody (N-term) - Images





The anti-EDG2 N-term Antibody (Cat.#AP6138a) is used in Western blot to detect EDG2 in A375 lysate.

# EDG2 Antibody (N-term) - Background

The EDG2 integral membrane protein is a lysophosphatidic acid (LPA) receptor from a group known as EDG receptors. These receptors are members of the G protein-coupled receptor superfamily. Utilized by LPA for cell signaling, EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion.

# EDG2 Antibody (N-term) - References

Matsuda, A., et al., Oncogene 22(21):3307-3318 (2003). Van Leeuwen, F.N., et al., J. Biol. Chem. 278(1):400-406 (2003). Shida, D., et al., Cancer Res. 63(7):1706-1711 (2003). Cervera, P., et al., Glia 38(2):126-136 (2002). An, S., et al., Mol. Pharmacol. 54(5):881-888 (1998). **EDG2 Antibody (N-term) - Citations** • The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.